A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

NCT05162365 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
248
Enrollment
INDUSTRY
Sponsor class

Stopped The company decision that terminated the further develop of the molecule and had notified FDA about the termination as well.

Conditions

Interventions

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.